Stock Analysis
Inhibrx Biosciences Inc. (INBX) Stock Analysis
Inhibrx Biosciences Inc. (INBX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Inhibrx Biosciences Inc. (INBX) currently has an AIQ Score of 40/100, indicating a bearish setup. Momentum is the strongest factor at 50/100. Quality is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
INBX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $83.30 |
| AIQ Score | 40/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $1.31B |
| P/E Ratio (TTM) | -9.19 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$2.46 |
| Revenue (Q3 FY2026) | $2M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 2.18 |
| Volume | 245.9K |
| 52-week range | $57.30-$155.29 |
| RSI 14 | 45.11 |
| 50-Day SMA | $95.27 |
| 200-Day SMA | $92.69 |
| Analyst Price Target | $245.00 |
| Next Earnings | — |
INBXInhibrx Biosciences Inc.
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum50
- Value—
- Quality28
- Risk resilience40
- Sentiment—
INBX Stock Analysis Summary
Inhibrx Biosciences Inc. (INBX) currently has an AIQ Score of 40/100, indicating a bearish setup. Momentum is the strongest factor at 50/100. Quality is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, INBX has AIQ Score of 40/100 with Momentum base of 50/100 and fading Quality at 28/100. Wait for component alignment before adding exposure.
Momentum (50/100) leads while Quality (28/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -5.07% stock move · INBX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is INBX Bullish or Bearish Right Now?
INBX currently has a bearish overall setup. Momentum is the strongest factor at 50/100, while Quality is weakest at 28/100. The current evidence suggests a bearish setup.
- - Analyst target implies +194.12% upside from the latest quote.
- - Risk Resilience is weak at 40/100.
- - Price is -10.13% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (32 vs 6).
Current Consensus
INBX's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 8 neutral, and 32 sell votes. INBX's 14-day RSI is 45.11, which places the stock in a neutral momentum range. INBX's beta is 2.18, indicating greater market sensitivity than the broad market.
What Changed in INBX?
The largest recent change in INBX is Momentum moving up by 12.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the INBX Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
INBX Decision Framework
Public evidence layers, setup checks, and risk context for Inhibrx Biosciences Inc..
Inhibrx Biosciences Inc. (INBX) Stock Analysis
Inhibrx Biosciences Inc. has an AIQ Score of 40/100 in a Bearish regime. Momentum is strongest at 50/100. Beta is 2.18, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | INBX is in a Bearish AIQ regime with score 40/100. |
| Signal Conflict | The primary conflict is that momentum leads at 50/100 while quality lags at 28/100. |
| Factor Evidence | Momentum 50/100 · Quality 28/100 · Risk 40/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 50/100.
Momentum is 50/100 and RSI (14) is 45.1.
INBX is in a Bearish regime at 40/100.
Risk factor is 40/100 with beta 2.18 and annual volatility 82.28%.
Current conflict: momentum leads at 50/100 while quality lags at 28/100.
INBX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
INBX Fundamentals
INBX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
INBX Technical Analysis
INBX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
INBX Stock Catalysts
Track INBX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
INBX Dividend Analysis
INBX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
INBX Financial Data
INBX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
INBX Risk Analysis
INBX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
INBX Stock News
INBX stock news, market tone, recent headlines, and catalyst context.
INBX vs Biotechnology Peers
Current peer cohort: INBX · INSM · INVA · IRON · JAZZ. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| INBX Current stock | 40/100 | — | 50/100 | 40/100 | 0.49 | 82.28% | Current |
| INSM Insmed Incorporated | 57/100 | 55/100 | 61/100 | 49/100 | -0.48 | 63.12% | INBX vs INSM |
| INVA Innoviva, Inc. | 67/100 | 92/100 | 43/100 | 74/100 | -0.64 | 25.21% | INBX vs INVA |
| IRON Disc Medicine, Inc. | 65/100 | — | 75/100 | 51/100 | 0.1 | 63.55% | INBX vs IRON |
| JAZZ Jazz Pharmaceuticals plc | 73/100 | 79/100 | 66/100 | 73/100 | 1.47 | 38.64% | INBX vs JAZZ |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for INBX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching INBX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for INBX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
INBX Stock FAQ
What is INBX stock price today?
Inhibrx Biosciences Inc.'s current stock price is $83.30. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is INBX bullish or bearish right now?
INBX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is INBX's market cap?
INBX's market cap is $1.31B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is INBX's current P/E ratio?
INBX's current P/E ratio is -9.19 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is INBX's RSI?
INBX's 14-day RSI is 45.11 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is INBX above its 50-day and 200-day moving averages?
INBX is -12.56% from its 50-day SMA and -10.13% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is INBX's next earnings date?
INBX's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does INBX pay a dividend?
INBX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.